MAD2L1BP

Across TCGA pan-cancer cohorts, MAD2L1BP RNA differs between tumor and matched normal tissue in 14 of 18 cancer types tested, making tumor–normal expression one of MAD2L1BP’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where MAD2L1BP RNA is more highly expressed in tumor relative to normal tissue. In most cancer types MAD2L1BP is over-expressed in tumor, although a few such as KICH and THCA show the opposite, repressed pattern.

HNSC, LIHC, and KICH are the cancer types where MAD2L1BP tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in MAD2L1BP RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	All	IV	+0.554	<.001	11	view →
LIHC	All	III,IV	+0.960	<.001	9	view →
KICH	Female	II,III,IV	−1.160	<.001	8	view →
KIRC	Female	All	+0.492	<.001	8	view →
KIRP	All	II,III,IV	+0.459	.002	8	view →
LUAD	All	II,III,IV	+0.335	<.001	7	view →
STAD	All	II,III,IV	+0.741	<.001	6	view →
BRCA	All	III,IV	+0.699	<.001	6	view →
CHOL	All	II,III,IV	+1.789	<.001	5	view →
UCEC	All	II,III,IV	+0.536	.024	4	view →
ESCA	All	II,III,IV	+0.670	.002	3	view →
BLCA	All	All	+0.321	.040	3	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 12 strongest of 14 lineages.

MAD2L1BP–HNSC

Open the HNSC breakdown →